Turner White CommunicationsAbout TWCSubscribeContact TWCHomeSearch
Hospital PhysicianJCOMSMPBRMsCart
Current Contents
Where We Are Indexed
Past Issue Archives
Clinical Communication
CME
Outcomes
Research
In Review
Editorial Board
Information for Authors
Author Form

Reprints, Permissions, & Copyright
Site Map
 
JCOM
BACK ISSUE articles are $15 each.
 
International credit cards NOT accepted.



JCOM Paid Subscribers
LOG IN
user name:
password:
 
Forgot password?

JCOM Abstract


J Clin Outcomes Manage 
2004 Sep;11(9):568-573
Spironolactone: the missing drug in the treatment of patients hospitalized with congestive heart failure
Sreih, A

Abstract Objective: To assess the impact of interventions to increase the use of spironolactone in patients with congestive heart failure (CHF) due to ventricular systolic dysfunction. Methods: Charts of patients admitted to the medicine department of a single hospital with a primary diagnosis of class IV CHF and left ventricular ejection fraction of 40% or less were randomly selected and reviewed. Data were obtained for 30 preintervention and 30 postintervention patients. Measures included rates of use of spironolactone, b blockers, and angiotensin-converting enzyme (ACE) inhibitors/angiotensin-receptor blockers (ARBs) and documentation of contraindications to these therapies. Interventions: Interventions consisted of adding a clinical decision support reminder to the physician order entry system that alerted physicians ordering ACE inhibitors/ARBs for CHF to consider adding b blockers and spironolactone, an educational program to raise awareness of guideline recommendations, and multidisciplinary efforts to identify patients with CHF on admission and communicate appropriate recommendations to the medical team. Results: The rate of spironolactone use was 0% in the preintervention sample and 40% in the postintervention sample. Use of ACE inhibitors/ARBs and b blockers did not differ between the preintervention group (73% and 66%) and postintervention group (67% and 60%). Documentation of contraindications to ACE inhibitors/ARBs and b blockers increased from 40% and 0% preintervention, respectively, to 100% and 60% postintervention. Conclusion: There was a substantial increase in the utilization of spironolactone in patients with systolic dysfunction after the implementation of relatively inexpensive interventions. We continue to look for systems improvements to further increase appropriate use of spironolactone and other evidence-based therapies.

Article

Search the Turner White index to find abstracts of articles published in JCOM.





New issues are posted one month following publication of the printed journal.



View past issue archives:    2013    2012    2011    2010    2009    2008    2007
   2006    2005    2004    2003     2002     2001     2000     1999



Hospital Physician     JCOM     Seminars in Medical Practice
Hospital Physician Board Review Manuals
About TWC    Subscribe    Contact TWC    Home    Search   Site Map

Copyright © 2014, Turner White Communications
Updated 1/20/14 • jdw